Biogen Idec is a profitable Fortune 500 company, a global biotechnology leader with more than $4 billion in revenue. With a pipeline that includes more than 20 products in Phase 2 clinical trials and beyond and more than 200,000 liters of world-class biologics production capacity spread across three facilities, we anticipate robust growth in 2010 and into the future.
Biogen Idec delivers its first-in-class and best-in-class treatments to patients in more than 90 countries. We have more than 4800 employees worldwide and a direct commercial presence in more than 28 markets, with a network of distribution partners in more than 70 others. We pursue our mission through a strategic combination of internal research and development and through partnerships, alliances, and acquisitions.
With an unshakeable commitment to our mission and values and our practice of innovation across the organization, we expect to build shareholder value while also helping patients with serious, unmet medical needs.
Important Information
Biogen Idec and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Biogen Idec in connection with the Company’s 2010 annual meeting of stockholders. The names, affiliations and interests of such individuals may be found in Biogen Idec’s Annual Report on Form 10-K for the year ended December 31, 2008 and its proxy statement for the 2009 Annual Meeting, each of which are filed with the Securities and Exchange Commission (SEC). To the extent holdings of Biogen Idec securities have changed since such documents were filed, such changes have been or will be reflected in Statements of Change in Ownership on Forms 3 and 4 filed with the SEC. Additional information regarding such individuals will be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009 and in the Company’s proxy statement in connection with the Company's 2010 annual meeting of stockholders when those documents are filed with the SEC.
Biogen Idec files annual, quarterly and special reports with the SEC. The proxy statements and other reports, when available, can be obtained free of charge at the SEC’s web site at www.sec.gov or from Biogen Idec at www.biogenidec.com. Biogen Idec stockholders are advised to read carefully the proxy statement relating to the Company’s 2010 annual meeting of stockholders and any other relevant documents filed by the Company with the SEC when they become available before making any voting or investment decision, because they will contain important information. The Company’s proxy statement will also be available for free by writing to Biogen Idec Inc., 14 Cambridge Center, Cambridge, MA 02142. In addition, copies of the proxy materials may be requested from our proxy solicitor, MacKenzie Partners, Inc., by toll-free telephone at 1-800-322-2885 or by e-mail at proxy@mackenziepartners.com.
CAMBRIDGE, Mass., Feb 08, 2010 (BUSINESS WIRE) -- Biogen
Idec (NASDAQ: BIIB), a global biotechnology leader in the discovery,
development, manufacturing and commercialization of innovative
therapies, today announced that John R. Richert, M.D., will be joining
the Company as a Senior Fellow in Neurology Research and Development and
Nancy D. Richert, M.D., Ph.D., will be joining as a Fellow in Neurology
Research and Development.
"We are extremely ex...
CAMBRIDGE, Mass., Jan 28, 2010 (BUSINESS WIRE) -- Biogen
Idec (NASDAQ: BIIB) today announced it has received notice from
Icahn Partners LP and certain of its affiliates of their intention to
nominate three individuals, Thomas F. Deuel, Eric K. Rowinsky and
Richard A. Young, to Biogen Idec's Board of Directors at the Company's
2010 Annual Meeting. The notice also includes a proposal to amend the
Company's bylaws to fix the number of directors at 12....
CAMBRIDGE, Mass. & STOCKHOLM, Jan 25, 2010 (BUSINESS WIRE) -- Biogen
Idec (NASDAQ: BIIB) and Swedish
Orphan Biovitrum (STO: BVT) today announced that the first patient
was dosed in a registrational, open-label, multicenter trial designed to
evaluate the safety, pharmacokinetics and efficacy of the companies'
long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in
hemophilia B patients. The trial, called the B-LONG study, will
d...
Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
0.69
